15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Ligand Pharmaceuticals Incorporated, 8 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $220.00 to $388.00, a moderate spread. The average target of $335.75 sits 16% above the current $289.03. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.01 next quarter toward $11.93 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Strong Buy
Strong Buy00%
Buy8100%
Hold00%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Ligand Pharmaceuticals Incorporated.
As of Sep, 8 of 8 firms rate LGND a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LGND EPS & revenue forecast
EPS · NEXT QUARTER
$3.01
Range $2.79 – $3.26 · 9 analysts · +49% YoY
Next period, 9 analysts expect Ligand Pharmaceuticals Incorporated to earn $3.01 a share (range $2.79 – $3.26), versus $2.02 a year earlier. Full-year consensus is $9.32, growing to $11.93 the year after.
REVENUE · NEXT QUARTER
$96.6M
Range $88.7M – $104.1M · 9 analysts · +62% YoY
Revenue is expected to reach $96.6M (range $88.7M – $104.1M), +61.9% year-over-year. Full-year consensus is $289.8M, rising to $380.5M next year.
Top analysts covering Ligand Pharmaceuticals Incorporated
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LGND.
#1
Balaji Prasad
Barclays · Rank #178
Buy
$160.00-44.6% to target
Overall win rate
44%
+ Follow
#2
DM
Douglas Miehm
RBC Capital · Rank #190
Buy
$345.00+19.4% to target
Overall win rate
43%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$387.00+33.9% to target
Overall win rate
41%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Buy
$358.00+23.9% to target
Overall win rate
34%
+ Follow
#5
Leland Gershell
Oppenheimer · Rank #307
Buy
$326.00+12.8% to target
Overall win rate
37%
+ Follow
LGND stock forecast FAQ
What is LGND's average 12-month price target?+
The 8 analysts with a live target average $335.75 for Ligand Pharmaceuticals Incorporated over the next 12 months, ranging from a $388.00 high to a $220.00 low.
Is LGND stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 8 analyst ratings, 8 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LGND?+
The Street-high target is $388.00 (B of A Securities), and the Street-low is $220.00 (Benchmark). The average of all 8 active targets is $335.75.
How many Wall Street analysts cover LGND?+
8 analysts have an active rating on Ligand Pharmaceuticals Incorporated, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering LGND?+
Among analysts who currently cover LGND, Balaji Prasad of Barclays has the strongest overall Quantellect track record (Rank #178). Their current call is Buy with a $160.00 target.
What is Ligand Pharmaceuticals Incorporated's projected EPS for next quarter?+
The consensus estimate is $3.01 per share (range $2.79 – $3.26) across 9 analysts. Full-year EPS is projected at $9.32, rising to $11.93 the following year.
How much revenue is Ligand Pharmaceuticals Incorporated expected to report next quarter?+
Consensus revenue is $96.6M (range $88.7M – $104.1M). Full-year revenue is projected at $289.8M, growing to $380.5M next year.
Have analysts been upgrading or downgrading LGND lately?+
As of Sep, 8 of 8 firms rate LGND a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LGND calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
